A joint American and Brazilian team recently studied a drug called proxalutamide as a treatment for COVID-19. A nonsteroidal antiandrogen (NSAA) under development, the hypothesis behind this trial was that TMPRSS2, regulated by the androgen receptor, hence SARS-CoV-2, infectivity is indirectly dependent on androgenic status and phenotype. Thus, a Phase 2 double blinded, randomized, placebo controlled prospective trial in mild to moderate COVID-19 patients. A non-hospitalized cohort but confirmed positive, key endpoints targeted included remission time (days) and the percentage of subjects confirmed negative on Day 7 after treatment. The study team concluded that this treatment serves to increase viral clearance of COVID-19 at Day 7 and reduce the average number of days to COVID-19 clinical transmission when compared to the placebo group.
During the continuing SARS-CoV-2 (COVID-19) pandemic, the sponsors of this study revealed that a number of studies revealed a significant difference in the rate of severe cases between adult females and adult males (42% vs 58%).Among children under the age of 14, the rate of severe cases was reported to be low compared to al...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).